Cargando…

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

Tyrosine kinase inhibitors are a class of chemotherapeutic drugs that target specific protein kinases. These tyrosine kinase inhibitors constitute a relatively new class of drugs which target for instance Bcr-Abl, Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Klerk, Daniel J., Honeywell, Richard J., Jansen, Gerrit, Peters, Godefridus J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315453/ https://www.ncbi.nlm.nih.gov/pubmed/30544701 http://dx.doi.org/10.3390/cancers10120503

Ejemplares similares

Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
por: Krchniakova, Maria, et al.
Publicado: (2020)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance
por: Ruzickova, Eliska, et al.
Publicado: (2019)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors
por: Benes, Cyril H
Publicado: (2015)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
por: Song, Xiaoling, et al.
Publicado: (2021)

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Mumenthaler, Shannon M., et al.
Publicado: (2011)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
por: Anreddy, Nagaraju, et al.
Publicado: (2014)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors
por: Podolski-Renić, Ana, et al.
Publicado: (2021)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
por: Van Der Steen, Nele, et al.
Publicado: (2020)

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors
por: Young, David J., et al.
Publicado: (2021)

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
por: Noordhuis, Paul, et al.
Publicado: (2019)

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
por: Wang, Yi-Jun, et al.
Publicado: (2014)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
por: Jansen, Gerrit, et al.
Publicado: (2023)

PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells
por: Zhao, Xin-min, et al.
Publicado: (2016)

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
por: Kawai, Hidetsugu, et al.
Publicado: (2019)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2020)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
por: Verhagen, Noor E., et al.
Publicado: (2023)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
por: Ohashi, Yoshimi, et al.
Publicado: (2017)

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
por: Kang, Minyong, et al.
Publicado: (2017)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases
por: Zhu, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g8pa9v0pkffp4agl954frduiiv